Workflow
Guolian Securities
icon
Search documents
境外新签高增,“两商”转型扎实推进
Guolian Securities· 2024-05-10 14:00
证券研究报告 公 2024年05月10日 司 报 告 中国化学(601117) │ 行 业: 建筑装饰/专业工程 公 投资评级: 买入(首次) 司 当前价格: 7.62元 境外新签高增,“两商”转型扎实推进 年 目标价格: 10.01元 报 点 公司发布23年年报和24年一季报,23fy营业总收入1,792亿元,yoy+13%; 评 基本数据 归母净利54亿元,同比+0%;扣非归母净利52亿元,yoy+4%。单季度看, 总股本/流通股本(百万股) 6,109.47/6,049.51 23q4/24q1公司营业总收入分别475/452亿,分别yoy+26%/+6%;归母净利 流通A股市值(百万元) 46,097.27 分别 17/12 亿,分别 yoy+0%/+10%;扣非归母净利分别 15/12 亿,分别 yoy+7%/+4%。 每股净资产(元) 9.62  境外新签延续高增,收入增长动能强劲 资产负债率(%) 70.06 分业务来看,23fy化学工程/基础设施/环境治理/实业及新材料/现代服务 一年内最高/最低(元) 10.04/5.68 业收入分别1,424/220/28/77/30亿元,分别yoy+2 ...
半成品上新暂承压,餐饮和奶油贡献加大
Guolian Securities· 2024-05-10 13:00
立高食品(300973) 证券研究报告 2024 年 05 月 10 日 行 业: 食品饮料/休闲食品 投资评级: 买入(维持) 当前价格: 36.56 元 目标价格: 44.70 元 半成品上新暂承压,餐饮和奶油贡献加大 事件: 公司公告 2023 年营收/归母净利润 34.99/0.73 亿元,同比增长 20.22%/- 49.21%;对应 2023Q4 营收 9.17 亿元,同比增长 6.67%,归母净利润-0.85 亿元。2024Q1 营收/归母净利润/扣非为 9.16/0.77/0.68 亿元,同比增长 15.31%/53.96%/40.29%。剔除股权激励对应的股份支付费用后,归属于上 市公司股东的净利润 0.81 亿元,较上年同期增长 22.3%。业绩略低于预期。 ➢ 收入端:奶油产品与餐饮渠道贡献加大 23 年公司冷冻烘焙半成品/烘焙原材料收入同比增长 24%/13%;流通渠道/ 商超/餐饮、茶饮及新零售收入占比 55%/30%/15%,收入同比基本持平 /+50%/+100%。24Q1 公司收入同比增长 15.31%,产品及渠道均有积极增长 点。(1)从产品来看,24 全年冷冻烘焙一是会继续 ...
2024年一季报点评:米兰纳及整装加速拓展,业绩同比高增
Guolian Securities· 2024-05-10 13:00
轻工制造/家居用品 买入(维持) 18.58 元 21.28 元 事件: 索菲亚发布 2024Q1 业绩公告:2024Q1 公司实现营收 21.11 亿元,同比 +16.98%;实现归母净利润 1.65 亿元,同比+58.59%;实现扣非后归母净利 润 1.56 亿元,同比+73.81%;实现基本每股收益 0.17 元/股,同比+50.78%。 2024 年公司让利于经销商,叠加材料采购成本有所上行,因此 2024Q1 毛利 率同比-0.63pct 至 32.62%。费用端来看,公司期间费率同比下降 3.43pct, 其中销售/管理/研发/财务费率分别同比-1.13/-0.93/-0.24/-1.13pct,主 要系公司利用数字化转型、大数据应用及智能制造等多项措施,不断提升 人效,销售费率同比下降;同时公司报告期内优化了借款结构,利息支出 减少,财务费用下行明显,Q1 整体净利率提升至 8.24%,同比+2.47pct。 未来索菲亚零售有望依靠橱柜、木门带动客单价提升,整装渠道维持高增, 降本增效改善盈利,预计 2024-2026 年营业收入为 131.26/146.95/164.29 亿 元 , 同 比 ...
价格下滑致业绩承压,高端氟材+制冷剂并进
Guolian Securities· 2024-05-10 08:00
证券研究报告 公 2024年05月10日 司 报 告 昊华科技(600378) │ 行 业: 基础化工/化学制品 公 投资评级: 买入(维持) 司 当前价格: 32.88元 价格下滑致业绩承压,高端氟材+制冷剂并进 年 目标价格: 37.49元 报 点 事件: 评 基本数据 4月29日,公司发布2023年年报,2023年公司实现营业收入78.52亿元, 总股本/流通股本(百万股) 911.47/903.95 同比下滑 13%;实现归母净利润 9.00 亿元,同比下滑 23%,扣非后归母净 流通A股市值(百万元) 29,721.77 利润8.11亿元,同比下滑16%;实现基本每股收益0.99元/股。 每股净资产(元) 9.52 公司发布2024年一季报,2024年Q1公司实现营业收入16.13亿元,同比 资产负债率(%) 44.42 下滑22%,环比增加2%;归母净利润1.37亿元,同比下滑40%,环比下滑 一年内最高/最低(元) 40.80/23.51 36%;销售净利率8.50%,同比下滑2.56pct,环比下滑5.00pct。  供需矛盾加剧,产品价格下滑致业绩承压 股价相对走势 公司23年业绩承压,主 ...
重视研发投入,股权激励提振发展信心
Guolian Securities· 2024-05-10 08:00
Investment Rating - The investment rating for the company is "Buy" based on a target price that is expected to exceed the market index by more than 20% [7]. Core Insights - The company has a strong focus on R&D, with a R&D expense ratio of 9.12% in Q1 2024, reflecting a year-on-year increase of 4.12 percentage points [9]. - The operating cash flow has significantly improved, reaching a net amount of 48 million yuan in Q1 2024, which is a 33.33% increase compared to the previous quarter [9]. - The company has set ambitious performance targets in its stock incentive plan, aiming for a net profit of at least 160% of the previous year's profit for 2024 [18]. Financial Performance Summary - In Q1 2024, the company reported revenue of 313 million yuan, a year-on-year decrease of 38.46%, and a net profit attributable to the parent company of 27,800 yuan, down 99.93% [2]. - The projected revenues for 2024-2026 are 2.094 billion, 2.585 billion, and 3.196 billion yuan, with year-on-year growth rates of 25.01%, 23.44%, and 23.62% respectively [4]. - The net profit attributable to the parent company for the same period is expected to be 163 million, 189 million, and 224 million yuan, with growth rates of 100.28%, 15.89%, and 18.20% respectively [4]. - The earnings per share (EPS) are projected to be 0.57, 0.66, and 0.78 yuan for 2024, 2025, and 2026, respectively, indicating a compound annual growth rate (CAGR) of 39.99% over three years [4]. Stock Performance - The company's stock price has shown relative performance against the CSI 300 index, with fluctuations of -40%, -3%, 33%, and 70% from May 2023 to May 2024 [5]. Valuation Metrics - The company has a current market capitalization of approximately 4.999 billion yuan, with a price-to-earnings (P/E) ratio of 39.6 for 2024 [11][21]. - The projected price-to-book (P/B) ratio is 3.7 for 2024, indicating a premium valuation compared to its book value [21].
行业需求略承压,龙头计划抢份额
Guolian Securities· 2024-05-10 08:00
证券研究报告 公 2024年05月10日 司 报 告 海天味业(603288) │ 行 业: 食品饮料/调味发酵品Ⅱ 公 投资评级: 增持(维持) 司 当前价格: 38.93元 季 行业需求略承压,龙头计划抢份额 目标价格: 43.29元 报 点 事件: 评 基本数据 公司发布2023年报及2024年第一季度报告,2023年公司实现营收245.59 总股本/流通股本(百万股) 5,560.60/5,560.60 亿元,同比-4.10%;实现归母净利润56.27亿元,同比-9.21%。2024Q1公 流通A股市值(百万元) 216,474.18 司实现营收76.94亿元,同比增长10.21%;归母净利润为19.19亿元,同 每股净资产(元) 5.43 比增长11.85%,公司业绩符合预期。 资产负债率(%) 17.01 ➢ 23年需求平淡,24Q1经营修复 一年内最高/最低(元) 68.27/33.02 分产品来看,2023年酱油实现营收126.37亿元,同比-8.83%,其中销量同 比下滑8.17%,均价下滑0.72%,营收下滑更多的来自量减,同时得益于公 股价相对走势 司在酱油品牌及产品升级方面取得进步,2 ...
年报及一季报点评:收入利润符合预期,分红率提升
Guolian Securities· 2024-05-10 08:00
Investment Rating - The investment rating for the company is "Buy" with a target price of 173.40 CNY [4]. Core Views - The company's revenue and profit for 2023 and Q1 2024 met expectations, with a revenue of 83.272 billion CNY in 2023, a year-on-year increase of 12.58%, and a net profit of 30.211 billion CNY, up 13.19% [1][2]. - The company demonstrated strong growth in its liquor products, achieving a revenue of 76.447 billion CNY in 2023, a 13.15% increase year-on-year, with the flagship product, Wuliangye, growing by 13.50% [1][2]. - The company's gross margin improved to 75.79% in 2023, with a net profit margin of 36.28%, indicating a steady enhancement in profitability [1][2]. Financial Performance Summary - In 2023, the company achieved a revenue of 83.272 billion CNY, with a growth rate of 12.58% [3]. - The projected revenues for 2024-2026 are 92.705 billion CNY, 102.631 billion CNY, and 112.929 billion CNY, with respective growth rates of 11.33%, 10.71%, and 10.03% [2][3]. - The net profit for 2024-2026 is expected to be 33.663 billion CNY, 37.305 billion CNY, and 41.167 billion CNY, with growth rates of 11.43%, 10.82%, and 10.35% [2][3]. Regional Performance - The company showed strong performance across various regions, with the Eastern region achieving a revenue of 22.389 billion CNY, a year-on-year increase of 17.92% [1]. - The total number of distributors increased to 3,384, with Wuliangye distributors reaching 2,570, reflecting a robust distribution network [1]. Profitability Metrics - The gross margin for Q1 2024 was reported at 78.43%, with a net profit margin of 40.32%, indicating strong profitability [1][2]. - The company's earnings per share (EPS) for 2024 is projected to be 8.67 CNY, with a three-year compound annual growth rate (CAGR) of 10.87% [2][3].
主业快速发展,股权激励彰显信心
Guolian Securities· 2024-05-10 08:00
亚辉龙(688575) 5 月 9 日,公司发布 2024 年限制性股票激励计划,公司拟向激励对象授予 175 万股限制性股票,占本激励计划草案公告时公司股本总额的 0.31%, 授予价格为 12.29 元/股,激励对象总人数共计 56 人,包括高级管理人员 ➢ 考核目标明确,彰显长期发展信心 2024Q1,公司非新冠自产营收 3.42 亿元(yoy+43.33%),其中国内自产 化学发光业务营收为 2.74 亿元(yoy+47.73%),海外自产化学发光业务营 收为 0.34 亿元(yoy+49.76%)。在装机方面,2024Q1 公司自产发光仪器 新增装机 418 台,其中国内 271 台(高速机占比达 47.23%),海外 147 台,流水线新增装机 16 条。截至 2024Q1,公司自产化学发光仪器累计装 机超 9240 台,流水线累计装机 108 条,新增装机有望带动后续试剂上量。 | --- | --- | --- | --- | --- | --- | |----------------------------|---------|------------------------------|- ...
对4月外贸数据的思考与未来展望:进出口回升有望持续
Guolian Securities· 2024-05-10 07:30
2024 年 05 月 10 日 ——对 4 月外贸数据的思考与未来展望 4 月中国以美元计价的出口同比增速为 1.5%,较 3 月(-7.5%)大幅回升。 季节性调整后,4 月出口继续环比正增长,较 3 月环比增长 0.7%。外需的 改善可能是出口环比回升的主要原因。4 月进口规模在季节性调整后,环比 也有明显上行(2.2%)。展望未来,我们认为,中国季节性调整后的出口规 模或能保持温和的环比正增长;同时,一季度经济超预期复苏,或正持续 验证我们经济新周期开启的观点,内需的修复也有望带动进口进一步增长。 4 月中国出口同比增速为 1.5%(美元计价),较 3 月(-7.5%)大幅回升。 经过季节性调整以后,4 月出口继续环比正增长,4 月以美元计价的出口金 额环比增速为 0.7%。在 3 月出口已经较 1-2 月平均的出口规模增长 0.9%的 基础上,4 月出口环比保持正增长,表明出口具有较强的韧性。 季节性调整后,不同产品出口表现延续分化:轻工、高新技术产品的出口 都有所反弹,环比分别增长 1.7%、1.2%;但原材料、农产品、机电产品的 出口都有一定的放缓,环比分别下降 7%、0.8%、1.7%。分出口 ...
原料+医疗终端业务亮眼,期待护肤业务重回增长轨道
Guolian Securities· 2024-05-10 07:30
Investment Rating - The report suggests a focus on the company's management and organizational adjustments, indicating a potential for recovery in performance, thus recommending attention to the stock [6]. Core Views - The company reported a revenue of 6.076 billion yuan in 2023, a decrease of 4.5% year-on-year, with a net profit of 593 million yuan, down 39.0% year-on-year. However, Q1 2024 showed a revenue increase of 4.2% year-on-year to 1.361 billion yuan and a net profit increase of 21.4% year-on-year to 243 million yuan [3][4]. - The raw materials and medical terminal businesses performed well in 2023, with raw material revenue increasing by 15.22% and medical terminal business revenue increasing by 58.95%. In contrast, the functional skincare segment saw a revenue decline of 18.45% due to strategic adjustments [4][5]. - The company is implementing multi-dimensional adjustments in management, digitalization, and business operations, aiming for a rebound in the skincare business in 2024 [5]. Financial Summary - Revenue projections for 2024-2026 are 7.095 billion yuan, 8.095 billion yuan, and 9.253 billion yuan, with corresponding growth rates of 16.8%, 14.1%, and 14.3%. Net profit projections are 863 million yuan, 1.051 billion yuan, and 1.272 billion yuan, with growth rates of 45.6%, 21.8%, and 21.1% respectively [6][7]. - The company's comprehensive gross margin for 2023 was 73.3%, with a net profit margin of 9.75% [4][6]. - The earnings per share (EPS) for 2024-2026 are projected to be 1.79 yuan, 2.18 yuan, and 2.64 yuan, respectively [6][7].